Articles tagged with Career Advice
Dr. Gobbi challenges the global drug-development system, stating that promising treatments for mental illness are failing to reach patients due to venture capital and profit motives. Her research focuses on cannabis, melatonin, and psychedelics, with a goal of improving public-health decisions and treatment outcomes.
A new study found that augmented reality job coaching significantly improves job performance for individuals with intellectual and developmental disabilities. The AR-based application delivered real-time guidance, enabling participants to complete complex tasks with minimal external support. This innovative approach has the potential t...
The University of Texas at Arlington receives a six-year $2 million NSF grant for math scholarships up to $15,000. The program aims to address the national STEM workforce need and nurture talent.
A new book reveals personal tales from successful scientists who overcame insecurities, health issues, and cultural norms to achieve their goals. The stories highlight that self-doubt is a common part of the scientific experience, but with support and resilience, it's possible to overcome.
Dr. Noritaka Ichinohe challenges the long-held assumption that averaging away individual differences is necessary in psychiatric research. Instead, biological heterogeneity is seen as a phenomenon demanding explanation. The author's work on primate brain mapping and molecular subtyping has identified convergence points between species ...
Dr. Eric J. Nestler's research has fundamentally reshaped global understanding of addiction and depression by focusing on resilience rather than pathology. His laboratory identified distinct molecular, cellular, and circuit changes in resilient brains that maintain normal behavioral function despite exposure to drugs or stress.
Japanese primary care physicians derive a sense of meaning from managing diverse health problems, fostering rapport through continuous care, and collaborating with other healthcare professionals. These experiences promote professional growth and contribute to broader societal goals, building fulfilling careers.
The Damon Runyon Cancer Research Foundation has named the newest cohort of SPARK Scholars, providing post-baccalaureate scholars with research training, mentors, and networking opportunities. The program's recipients will conduct cancer research in top institutions and present their findings at the annual Damon Runyon Fellows' Retreat.
Groundbreaking research by Dr. Bruce M. Cohen has uncovered critical abnormalities in energy metabolism and cellular connectivity that contribute to psychiatric disorders. The study's findings suggest therapeutic avenues that may be better targeted and more effective than current treatments.
Dr Oliver Pain develops GenoPred platform advancing personalized mental healthcare worldwide through accessible genetic tools, democratizing access to cutting-edge genomic methodologies. His work aims to reduce global health inequities by developing inclusive polygenic scoring methods that perform accurately across all ancestry groups.
A study by Dr. Esther Sternberg highlights the importance of social engagement, intellectual stimulation, purposeful activity, humor, and spiritual exploration in achieving exceptional cognitive and social functioning in advanced age. Dr. Reichlin's example challenges conventional assumptions about aging trajectories.
Dr. Gerhard Andersson's pioneering work in internet-delivered cognitive behavioral therapy has produced over 200 controlled trials and transformed mental healthcare accessibility across continents.
Six Japan-led programs will be presented at the Science Summit UNGA80, addressing global challenges such as food and water security, rare diseases, inclusive education, and research ethics. The programs are open to a global audience and offer free registration.
Dr. Harriet de Wit's groundbreaking research bridges animal and human drug studies, demonstrating that MDMA enhances feelings of social connectedness and challenging addiction treatment strategies. Her discoveries have profound implications for treating trauma-related disorders globally.
Research reveals neuroglia play active role in brain function, driving disease progression through atrophy and functional decline. Therapeutic strategies targeting neuroglial signaling may prevent damage following brain injury or protect against neurodegenerative processes.
Dr. David Rubinsztein shares his personal journey from childhood curiosity to discovering autophagy, a natural process that clears toxic proteins causing devastating neurodegenerative diseases. His research has established autophagy upregulation as a viable therapeutic strategy for conditions affecting millions worldwide.
Dr. David Rubinow's research reveals that susceptible women respond differently to normal hormonal fluctuations, leading to breakthrough treatment approaches and FDA-approved medication for postpartum depression. His work validates the experiences of millions of women whose hormone-related mood symptoms were previously misunderstood.
Dr. Camilo de la Fuente-Sandoval has developed a groundbreaking approach to schizophrenia treatment prediction using neuroimaging and comprehensive clinical care. His team's research reveals elevated glutamate levels in the associative striatum that normalize with effective antipsychotic treatment.
The Living Brain Project at Mount Sinai has collected over 300 brain tissue samples, revealing that 80% of genes exhibit different expression levels in living versus postmortem brain tissue. This challenges decades of neuroscience research based on postmortem samples.
Six UNH faculty members receive prestigious CAREER grants to develop innovative technologies addressing pressing global issues. The recipients' projects focus on climate resilience, artificial intelligence, software reliability, and healthcare technologies, aiming to improve public safety and well-being.
Aging and depression are linked to complex brain-body communication, with organs aging at different rates and influencing disease susceptibility. Dr. Hamilton Oh's research reveals how immune cells and metabolic organs amplify or dampen mood symptoms, offering novel therapeutic targets.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
Dr. Randy J. Nelson's research reveals that artificial light exposure disrupts immune function, causes neuroinflammation, and influences mood regulation. His work has significant implications for understanding depression and anxiety disorders, as well as the obesity epidemic.
Dr. Xuyu Qian's pioneering research using MERFISH technology created an unprecedented developmental atlas of the human cerebral cortex, analyzing over 18 million single cells. His work aims to identify mechanisms disrupted in conditions like malformations and autism spectrum disorder.
Dr. John Oldham's contributions have fundamentally reshaped personality disorder classification, moving from rigid categories to a more nuanced dimensional system. His Alternative DSM-5 Model for Personality Disorders (AMPD) has marked the most significant epistemological shift in psychiatric diagnosis for decades.
Sara Poletti's research reveals how childhood trauma triggers persistent neuroinflammation pathways and alters brain structure, creating lifelong vulnerability to psychiatric disorders. Her work identifies biological markers of trauma and explores prevention strategies to reduce mental illness odds.
A pioneering research brings psychedelic medicine into gastroenterology, exploring psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS). Dr. Erin E. Mauney's study modulates interoception and uses integrated therapy sessions with neuroimaging to track brain changes.
Professor Benedetti's research explores the intersection of genetics, environmental factors, and treatment response in mood disorders. His work has led to breakthroughs in chronotherapeutics and immuno-psychiatry, revealing crucial insights into immune-inflammatory mechanisms and gene variants influencing brain function.
A study by Carnegie Mellon University and the University of Kentucky found that employees assigned to more complex projects during their first two years had higher levels of learning, professional certifications, and promotion rates. This suggests that early career experiences play a crucial role in shaping future career development.
Dr. Yehezkel Ben-Ari's Neuroarcheology framework links developmental mechanisms to disorders, offering new hope for previously untreatable conditions. His groundbreaking work has transformed our understanding of brain development and malfunctions.
Researchers have found that psychedelic compounds can reverse a cascade involving brain-resident cells and immune cells, increasing fear behavior when chronic stress disrupts signaling. This finding represents a paradigm shift in understanding psychedelics' therapeutic potential.
Dr. Seymour Reichlin's remarkable career spanned five decades, marked by scientific excellence, mentorship, and generosity. His influence on neuroendocrinology has been profound, with ongoing contributions at age 100 revealing new insights into Alzheimer's disease and ecstatic mysticism.
Researchers using multi-omics tools analyze blood-derived immune cells to chart disease heterogeneity in unprecedented detail. This approach enables exploration of pre-existing immune states shaped by past infections, environmental exposures, and genetic predisposition.
Dr. Romina Mizrahi's PET-based neuroimaging sheds light on brain workings, integrating genetics, environment and imaging to understand psychiatric illness as a complex biological puzzle. She advocates for precision psychiatry paradigm with customized treatments based on molecular profiles, and calls for diversity in academic leadership.
The partnership aims to identify workforce trends and solutions, with a focus on apprenticeships, stackable credentials, and career pathways. Initial research findings are expected by the end of this year and will serve as a model for other states.
Dr. David Winchester will lead the American College of Cardiology's Board of Governors, guiding chapters representing all 50 states and promoting heart health improvement in communities. His term aims to address practice challenges through advocacy and chapter support.
Researchers at the University of Kansas are partnering with regional high schools to train about 500 students in AI coding and microelectronics. The program aims to develop a workforce that can specialize in AI and microelectronics, with a focus on community-centered projects and altruistic goals.
Dr. Melissa Perreault's research combines cutting-edge science with Indigenous knowledge, pioneering sex-specific biomarkers, neuroethics, and psychedelics research in neuropsychiatry. Her work aims to promote inclusive methodologies that consider diverse worldviews and cultural understandings of health.
The Minoritised Life Scientists Future Forum conference will take place in March 2025 at ICC Birmingham, aiming to foster an inclusive space for underrepresented life scientists. The event offers mentorship schemes, networking opportunities, and inspiring speakers from diverse backgrounds.
Dr. Kerry Ressler's research bridges the gap between molecular neuroscience and clinical psychiatry to understand PTSD's genetic architecture. Recent breakthroughs have identified over 100 significant genetic loci, representing a major step toward translating scientific discoveries into effective treatments.
A new study reveals that job satisfaction follows a U-shaped curve among managerial and professional workers during their 40s and 50s. This challenges societal perceptions of midlife and highlights the need for workplace support for skilled workers.
A new study by Columbia University Mailman School of Public Health evaluated the career services programs and employment outcomes of its graduates. The study found that neither program usage nor employment outcomes were statistically different by race or ethnicity, with room for improvement in other areas.
Dr. Cathy Barr's groundbreaking research sheds light on the genetic foundations of conditions including depression, ADHD, reading disabilities, and Tourette syndrome. Her work has the potential to lead to more targeted treatments and reduce stigma around psychiatric disorders.
Renowned neuroscientist Dr. Michael Meaney discusses his pioneering work on the intricate relationship between genes and environment in shaping brain health, with implications for public health policy and early intervention programs.
Emory University MD candidate Fayzan Rab's research investigates the economic and public health implications of psychedelic therapy implementation. His work emphasizes making these innovative treatments accessible to traditionally underserved communities.
Neuroscientist Professor Raz Yirmiya reveals a vital link between inflammation and depression through groundbreaking research. His work suggests that both activation and suppression of the immune system can trigger depressive symptoms, highlighting the need for personalized treatment approaches.
Neuroscientist Inga Neumann discusses groundbreaking research on oxytocin, a neuropeptide that shapes social behavior and emotional responses. Her work has significant implications for treating social anxiety disorders and understanding stress resilience.
Dr. Munir Gunes Kutlu's groundbreaking research reveals specific neural mechanisms that transform sensory inputs into behavioral outputs. The discovery sheds light on the brain's dopamine system, particularly in processing information about environmental cues and rewards.
Renowned neuroscientist Dr. Peter Kalivas discusses his groundbreaking work on the tetrapartite synapse, a complex cellular structure influencing addictive behaviors. His research has revolutionized addiction treatment by identifying novel therapeutic targets beyond traditional neurotransmitter systems.
Dr. Edo Ronald de Kloet shares insights on cortisol's dual role in protecting and damaging the brain through mineralocorticoid receptors (MR) and glucocorticoid receptors (GR). His discovery has transformed our understanding of stress-related mental disorders and led to novel therapeutic pathways.
Research by Prof. Falkai suggests promising new directions in schizophrenia treatment through brain plasticity and myelin regeneration. His work challenges traditional views of the disorder and opens new therapeutic possibilities, particularly when combining aerobic exercise with a repurposed drug.
Professor Lavretsky's pioneering work integrates conventional psychiatric treatments with mind-body interventions, developing novel therapeutic combinations for treatment-resistant depression and cognitive disorders. Her research has transformed approaches to mental health and aging, emphasizing whole person health and prevention.
Dr. Seymour Reichlin's centennial celebration highlights his ongoing scientific impact, with recent collaborations yielding new insights into hormone therapies for cognitive enhancement and emotional homeostasis. His work has established neuroendocrinology as a distinct field, bridging neuroscience, endocrinology, and clinical medicine.
Dr. Natalia Acosta-Baena has identified a novel genetic syndrome that reshapes our understanding of brain disorders and challenges traditional views on neurodevelopmental disorders and neurodegeneration. Her research reveals how a single gene involved in neuronal transport can influence both brain development and degeneration.
Dr. Etienne Sibille's work develops novel therapeutics for cognitive deficits in depression and age-related disorders through Damona Pharmaceuticals, a biopharma company he co-founded.
Professor Amal's research has uncovered crucial links between autism spectrum disorder (ASD) and Alzheimer's disease, suggesting shared molecular mechanisms that could revolutionize treatment approaches. He is developing biological diagnostics and treatments for ASD through his biotechnology companies, Point6 Bio Ltd and NeuroNOS Ltd.
Dr. Andreazza's work focuses on identifying biomarkers for personalized treatments in metabolic psychiatry, with breakthroughs in brain organoids and mitochondrial transplantation techniques. Her innovative approach aims to revolutionize treatment for both psychiatric and metabolic disorders.
Dr. Volkow emphasizes the importance of prevention strategies and research on stress, trauma, and social determinants in substance use disorders. She also highlights promising new directions in treatment, including GLP1 medications, to address the treatment gap in addiction.
Dr. Reichlin's groundbreaking work on brain-hormone interactions and his influence on generations of endocrinologists are being celebrated through a Festschrift series in Brain Medicine. The series explores multiple facets of his contributions, including pioneering work on hypothalamic control of pituitary function and early recognitio...
Dr. Andero Galí's groundbreaking research connects mouse and human fear responses, using techniques like in vivo calcium imaging in mice and human fear response studies. His approach aims to create a more comprehensive understanding of the human brain by breaking down traditional barriers between animal and human studies.